June 3, 2022 | Press Releases

More than 40,000 oncology professionals from around the world will convene at the annual American Society of Clinical Oncology (ASCO) meeting this year in Chicago, IL and online. The ASCO annual meeting is a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in global cancer care, and the Prostate Cancer Clinical Trials Consortium (PCCTC) is pleased to present 11 abstracts detailing work from our multicenter clinical trials this year.


Phuoc T. Tran, et al. Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial. Abstract #5012 | Poster #196


Ulka N. Vaishampayan, et al. A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).  Abstract #5016 | Poster #200


Maha H. A. Hussain, et al. BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects. Abstract #5018 | Poster #202


Matthew Dallos, et al. A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8). Abstract #5082 | Poster #265


Tamim Niazi, et al. DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. Abstract #TPS5103 | Poster #281a


Evan Y. Yu, et al. DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Abstract #e17029


Mark N. Stein, et al. A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. Abstract #TPS5097 | Poster #278a


Alexandra Sokolova, et al. Trial in progress: Durvalumab and olaparib for the treatment of prostate cancer in men predicted to have a high neoantigen load. Abstract #TPS5099 | Poster #279a


Daniel C. Danila, et al. A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Abstract #TPS5101 | Poster #280a


Michael J. Morris, et al. Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. Abstract #TPS5104 | Poster #281a

Committed to world-class science!

Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.